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Email: chiaravilla@hotmail.it)AbstractMutations of the aryl hydrocarbon receptor interacting protein (AIP) gene are associated with
pituitary adenomas that usually occur as familial isolated pituitary adenomas (FIPA). Detailed
pathological and tumor genetic data on AIP mutation-related pituitary adenomas are not sufficient.
Non-identical twin females presented as adolescents to the emergency department with severe
progressive headache caused by large pituitary macroadenomas require emergency neuro-
surgery; one patient had incipient pituitary apoplexy. Post-surgically, the patients were found to
have silent somatotrope adenomas on pathological examination. Furthermore, the light
microscopic, immunohistochemical, and electron microscopic studies demonstrated tumors of
virtually identical characteristics. The adenomas were accompanied by multiple areas of pituitary
hyperplasia, which stained positively for GH, indicating somatotrope hyperplasia. Genetic
analyses of the FIPA kindred revealed a novel E216X mutation of the AIP gene, which was
present in both the affected patients and the unaffected father. Molecular analysis of surgical
specimens revealed loss of heterozygosity (LOH) in the adenoma but showed that LOH was not
present in the hyperplastic pituitary tissue from either patient. AIP immunostaining confirmed
normal staining in the hyperplastic tissue and decreased staining in the adenoma in the tumors
from both patients. These results demonstrate that patients with AIP germline mutation can
present with silent somatotrope pituitary adenomas. The finding of somatotrope hyperplasia
unaccompanied by AIP LOH suggests that LOH at the AIP locus might be a late event in a
potential progression from hyperplastic to adenomatous tissue.Endocrine-Related Cancer (2011) 18 347–356Introduction
Pituitary adenomas are the most common tumors
arising in the pituitary gland, with a prevalence of
about 17% in unselected autopsy and radiologicalEndocrine-Related Cancer (2011) 18 347–356
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pituitary tumors have prevalence in the general
population of w1:1064 to 1:1288 (Daly et al. 2006,
Fernandez et al. 2010). Pituitary adenomas carry aBritain
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Figure 1 Radiological imaging studies. Panels A and C,
contrast enhanced MRI of the brain in patient 1 showing a
pituitary macroadenoma of 25!20 mm, compressing the optic
chiasm with an area of hemorrhage or necrosis. Panels B
and D, contrast-enhanced brain MRI of patient 2 with a pituitary
macroadenoma of 32!35 mm with compression of the optic
chiasm and heterogeneous uptake of contrast agent; this tumor
was found to be hemorrhagic on emergency surgery.
C Villa et al.: AIP mutation and hyperplasia–adenomaheavy clinical burden due to the effects of hormonal
hypersecretion or deficiency, damage to important
local structures, and the necessity for invasive surgery
and/or chronic medical therapy. Multiple molecular
genetic alterations related to pituitary adenomas have
been identified, mainly as somatic mutations in
sporadic tumors (Asa & Ezzat 2009). Familial pituitary
adenomas are infrequent (5% of the total) but are of
clinical interest due to the possibility for earlier
diagnosis of tumors via screening for germline genetic
mutations (Daly et al. 2009a).
Established syndromes that are associated with
familial pituitary adenomas include multiple endocrine
neoplasia type 1 (MEN1), due to MEN1 gene
mutations, and acromegaly occurring as a component
of the Carney complex (CNC), associated with
PRKAR1A gene mutations (Bertherat et al. 2009,
Daly et al. 2009b). Inactivating mutations of the
CDKN1B gene cause MEN4, a rare condition
potentially associated with inherited pituitary tumor
risk (Pellegata et al. 2006, Agarwal et al. 2009).
Pituitary adenomas also occur in a familial setting in
the absence of MEN1 and CNC, in familial isolated
pituitary adenoma (FIPA) kindreds (Beckers & Daly
2007). Vierimaa et al. (2006) reported that inactivating
mutations of the aryl hydrocarbon receptor interacting
protein gene (AIP) occurred in families with pituitary
adenomas. AIP mutations account for 15% of FIPA
families (Daly et al. 2007) and may be found in 4–5%
of patients with acromegaly (Cazabat et al. 2009).
AIP mutation-related pituitary adenomas are typically
seen in young patients, are large and commonly
invasive at diagnosis, and are usually somatotropinomas
or prolactinomas, although rare cases of non-secreting
adenomas and other subtypes also occur (Daly et al.
2010).AIPmay act as a tumor suppressor gene, as loss of
heterozygosity (LOH) occurs in pituitary tumor tissue
(Vierimaa et al. 2006), although AIP immunostaining
is abolished in only a minority of tumors from AIP
mutation-bearing patients (Jaffrain-Rea et al. 2009).
AIP overexpression in vitro decreases cell proliferation
(Leontiou et al. 2008), AIP gene silencing results in
cell proliferation (Heliovaara et al. 2009), and recent
results from an Aip knockout mouse match the human
phenotype (Raitila et al. 2010).
We describe the detailed morphological and
pathological features of pituitary tumors in a new
FIPA family with a novel AIP mutation, paying
particular attention to somatic genetic status of AIP
in surgical samples that revealed features of pituitary
hyperplasia, which is a novel pathological topic
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Patients and family history
The index case was a 17-year-old female, who was first
seen at our institution in December 2008. She had a
4-week history of headache that had rapidly worsened
in severity over the preceding 48 h, the pain being
resistant to opiate analgesia. There was no grossly
diminished visual acuity (perimetry was not perfor-
med). Minor galactorrhea was present bilaterally,
menses were regular, and no other clinical evidence
of endocrine dysfunction was apparent. Medical
history was notable only for asthma. At presentation,
her height and weight were 166 cm and 75 kg
respectively.
Magnetic resonance imaging (MRI) of the brain
revealed a pituitary macroadenoma measuring
25!20 mm that compressed the optic chiasm and
had evidence of necrosis/hemorrhage (Fig. 1A and C).
Pituitary hormone levels were within the normal range.
In view of the severe presentation, the patient under-
went emergency tumor resection through a direct
paraseptal transsphenoidal approach; the tumor was
fully excised. After surgery, she developed transitory
diabetes insipidus and secondary adrenal deficiency.
In June 2009, a follow-up MRI showed no evidence
of recurrence.
During investigation of patient 1, family history
revealed that in October 2003 her non-identical twin
sister presented with a pituitary tumor elsewhere, at the
age of 12 years. The clinical presentation was a rapidly
progressive headache over the previous 3 weeks
associated with vomiting. There was a sudden loss in
visual acuity immediately before presentation and
papilledema was present on examination. The patient’s
height and weight were 162 cm and 62 kg respectively;
she also suffered from bronchial asthma. No features of
acromegaly or other signs/symptoms suggestive of
an endocrine abnormality were present. On MRI she
had a large pituitary adenoma measuring 32!35 mm
with suprasellar extension, compression of the optic
chiasm and heterogeneous uptake of the contrast agent
(Fig. 1B and D). Preoperative hormonal evaluation was
not performed. Owing to a high suspicion of pituitaryFigure 2 Genealogy and AIP sequencing information. Panel A,
genealogic tree of the immediate family of the affected patients
indicating AIP genotype and polymorphism data. Panel B, the
sequences of AIP demonstrating germline E216X mutations in
the two affected patients and in the unaffected father and the
wild-type sequence in the mother are shown. Panel C, loss of
heterozygosity (LOH) at the AIP locus in samples of tumor DNA
from the pituitary adenomas of both affected sisters; DNA
extracted from zones of hyperplasia or residual adenohypo-
physis did not show similar LOH.
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apoplexy, the patient underwent an emergency
sub-frontal craniotomy that demonstrated a giant
(O40 mm maximum diameter) hemorrhagic pituitary
adenoma. The patient developed hypopituitarism and
permanent diabetes insipidus post-operatively. Normal
visual acuity was re-established. Follow-up MRIs in
2006 and 2009 showed no recurrence. The patient’s
height at age 17 was 170 cm and she weighed 92 kg.
The genealogy is shown in Fig. 2A. The patients’
mother was 56 years old (weight: 79 kg, height:
160 cm) from Morocco. She had no medical history
of note. The father was aged 48 years (weight: 90 kg,
height: 189 cm) and from Algeria; he had no relevant
medical history and normal basal pituitary hormone
levels. The older sister of the two patients was aged
20 years, suffered from bronchial asthma, and had
normal pituitary hormone studies. The mother, father,
and sister declined MRI. A younger brother was born
in 1998 with Down syndrome and a severe congenital
cardiac abnormality and died at the age of 1 year due
to bronchiolitis and heart failure. Other members of
the kindred predominantly lived in North Africa and
were unavailable for or declined medical assessments.
The patients’ father had 13 siblings; all were well and
reported no endocrine/neurologic/oncologic diseases.
The paternal grandparents died due to heart failure
and smoking-related lung cancer. The maternal grand-
mother and 12 siblings of patients’ mother were aliveA B
D E
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350and well; the maternal grandfather had died of causes
unrelated to endocrine or oncologic pathologies.Genetic studies
Based on the familial presentation of pituitary
adenomas, the patients and first-degree relatives
underwent screening for germline mutations of the
MEN1 gene. As there was no clinical evidence or
features of CNC, PRKAR1A screening was not
warranted. The patients met the criteria for FIPA and
underwent germline screening for an AIP mutation.
All individuals and their guardians provided written
informed consent for clinical and genetic investi-
gations, and the study was performed according to the
Declaration of Helsinki.
For AIP and MEN1 studies, genomic DNA was
extracted from peripheral blood using the QIAamp
DNA Blood Midi kit and from paraffin-embedded
surgical pituitary specimens using the QIAamp
DNA mini kit (Qiagen). Isolated DNA was submitted
to spectrophotometric quantization and then to quality
assessment using b-actin PCR. The PCR/sequencing
primers and conditions for AIP analysis were as
described previously (Vierimaa et al. 2006). The PCR
productswere visualized on agarose gels using ethidium
bromide and were then purified by QIAquick PCR
purification kit (Qiagen).C
F
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Direct sequencing of the AIP gene was performed
using Big Dye 1.1 Terminator on an ABI PRISM
310 Genetic Analyzer (Applied Biosystems, Foster
City, CA, USA). Reference AIP sequences were down-
loaded from the EMBL nucleotide database (accession
number ENST00000279146) and matched with
the NCBI database (GenBank Accession number
NM_003977.2).MEN1 gene sequencingwas performed
with the BigDye Terminator on an ABI377 DNA
sequencer (Applied Biosystems). Chromatograms were
analyzed using the Lasergene Navigator Software
(GATC, Koustauz, Germany) and blasted against
the published MEN1 genomic sequence (GenBank
accession number U93237).
Histological studies
Pituitary surgical samples were fixed in formalin and
embedded in paraffin. Sections 5 mm thick were stained
with hematoxylin–eosin, periodic acid-Schiff, and
reticulin for light microscopy. Immunostains for all
anterior pituitary hormones, CAM5.2, MIB1/Ki67,
chromogranin A, Pit-1, and AIP, were performed as
described elsewhere (Villa et al. 2008, Jaffrain-Rea
et al. 2009).
An ultrastructural study was performed as described
previously (Villa et al. 2008), which was limited by the
formalin-fixing and paraffin-embedding protocol to the
evaluation of secretory granule diameter and cyto-
plasmic distribution (for detailed discussion ofA B
D E
Figure 4 Histological characterization of pituitary adenoma of pa
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www.endocrinology-journals.orgultrastructural findings in AIP-mutated pituitary ade-
nomas, see Leontiou et al. (2008)). Before tissue
microdissection was performed, normal, adenomatous,
and hyperplastic pituitary tissues were identified using
reticulin staining. Multiple well-defined sites from
pathological specimens were identified in this way for
microdissection: normal pituitary (nZ3), adenoma
(nZ5) and hyperplastic tissue (nZ4). An initial
5 mm-thick tissue section was stained with reticulin
for light microscopic examination; subsequently, ten
7 mm-thick serial sections were cut for manual tissue
microdissection. An eleventh 5 mm-thick section was
stained with reticulin in order to control for changes in
the distribution of pathological and normal pituitary
tissue areas. Manual scraping of different pituitary
tissue areas in all ten 7 mm-thick serial tissue sections
was performed using a fine needle tip. The resulting
paraffin-embedded material was collected for DNA
extraction (Kristiansen 2010).Results
Genetic analysis
Both affected patients had a novel heterozygous
E216X AIP mutation in exon 5 (Fig. 2B). The
clinically unaffected father was a carrier of this
mutation, whereas the mother and older sister were
of wild-type. Both patients and both parents were
heterozygotic for the previously described Q228KC
F
tient 2. Panel A, hematoxylin and eosin stain fragments from
small round cells with acidophil cytoplasm (!20 magnification).
eticulin pattern (!20 magnification). Panel C, the adenoma
asmic or Golgi-like pattern (!40 magnification). Panel D, on
lls as well in one mitosis (!20 magnification). The proliferation
, Pit-1 immunostain shows homogeneous nuclear expression in
matory cells) (!40 magnification). Panel F, AIP immunostain
!40 magnification). Only scattered cells were positive for AIP.
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Figure 5 Histological characterization of pituitary hyperplasia of patient 1. Panel A, reticulin stain of residual normal
adenohypophysis (!10 magnification). Panels B and C, in areas of hyperplasia, the reticulin fiber network is preserved but the
acini are expanded compared with normal adenohypophysis (!10 magnification). Panel D, transformation zone from hyperplasia to
adenoma (!10 magnification). From the left side to the right side of this panel, the reticulin fiber network shows a gradual disruption.
Panels E and F, diffuse, cytoplasmic GH immunoreactivity observed in hyperplastic acini (!10 magnification). Panel G,
homogeneous nuclear expression of Pit-1 was observed in hyperplastic acini (!20 magnification). Panel H, AIP immunostain is
strong and cytoplasmic in hyperplastic acini (!40 magnification).
C Villa et al.: AIP mutation and hyperplasia–adenoma(rs641081) polymorphism; the older sister was homo-
zygotic for this polymorphism. Sequencing of AIP in
tumor tissue revealed LOH in adenoma samples from
both patients (Fig. 2C). In contrast, LOH for the AIP
gene was found in neither the hyperplastic nor the
normal pituitary DNA samples.
MEN1 gene sequencing demonstrated wild-type
sequences in all patients and subjects apart from the
mother who had a previously described exon 10
polymorphism/missense mutation A541T (Bazzi
et al. 2008). No clinical evidence consistent with a
diagnosis of MEN1 was found in the mother.Histopathology
Histopathological findings from the pituitary tumors
of both patients were very similar. Both had tissue
fragments with a solid architectural pattern of
predominantly small round cells with acidophil cyto-
plasm (Figs 3A, B and 4A, B). There was evidence
of infarction, hemorrhage (patient 1), and ischemia
(both patients).
Reticulin staining revealed total breakdown of the
reticulin pattern in adenomatous tissue (Figs 3B and
4B), although expanded acini with a well-developed
reticulin fiber network were observed in areas of
pituitary hyperplasia (Figs 5B, C and 6B, C). Regions
of normal pituitary as well as zones of transition from
hyperplasia to adenoma were also observed (Figs 5A,
D and 6A, D).
Immunohistochemistry of both tumors showed
scattered GH and rare prolactin-positive cells (Figs
3C and 4C). Areas of pituitary hyperplasia showed a
diffuse cytoplasmic GH immunoreactivity (Figs 5E,
F and 6E). All adenoma fragments and hyperplastic352areas were immunoreactive for Pit-1 (Figs 3E, 4E, 5G
and 6G). In the tumor of patient 1 , the Ki-67/MIB1
proliferation index was 3%, with mitotic activity !1
mitosis per 10 high-power fields (HPF), while in
patient 2, the proliferation index in the adenoma was
5% with seven mitoses per 10 HPF (Figs 3D and 4D).
Rare cells in hyperplastic areas were positive for
MIB1/Ki67, whereas in residual normal pituitary, only
exceptional cells appeared immunoreactive (Fig. 6F).
Rarely, tumor cells expressed CAM5.2 with a
perinuclear ‘dot-like’ pattern. AIP staining was weak
and scattered in both adenomas and localized to the
cytoplasm. In contrast, AIP staining was strongly
positive in the hyperplastic areas (Figs 3F, 4F, 5H and
6H) and in normal pituitary.
The ultrastructural featureswere suggestive of sparsely
granulated adenomas. The diameter of the sparse,
spherical, electron-dense, cytoplasmic secretory granules
ranged from 110 to 290 nm (mean: 180 nm) in patient 1
and from 120 to 280 nm (mean: 200 nm) in patient 2.
Tumor from patient 2 also demonstrated some densely
granulated cells, with granules of 190–480 nm (mean:
335 nm) in diameter. According to the definition of silent
pituitary adenoma proposed by the AFIP and WHO
classification of pituitary tumors, the pathological
diagnosis in both cases was consistent with a silent
somatotrope adenoma (Asa 2008, Osamura et al. 2008).Discussion
In this study, we describe a new FIPA kindred in which
non-identical female twins presented in adolescence
with pituitary macroadenomas in association with a
novel E216X mutation of AIP. These patients highlightwww.endocrinology-journals.org
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Figure 6 Histological characterization of pituitary hyperplasia of patient 2. Panel A, reticulin stain of residual normal
adenohypophysis (!10 magnification). Panels B and C, in areas of hyperplasia, the reticulin fiber network is preserved but the
acini are expanded compared with normal adenohypophysis (!10 magnification). Panel D, transformation zone from hyperplasia
to adenoma (!10 magnification). From the left to the right side of Panel D, the reticulin fiber network shows a gradual disruption.
Panel E, a diffuse, cytoplasmic GH immunoreactivity is observed in hyperplastic acini (!10 magnification). Panel F, on MIB1/Ki67
immunostain, nuclear expression is observed in rare cells in a hyperplastic area (!10 magnification). Panel G, homogeneous
nuclear expression of Pit-1 was observed in hyperplastic acini (!10 magnification). Panel H, AIP immunostain is strong and
cytoplasmic in hyperplastic acini (!40 magnification).
Endocrine-Related Cancer (2011) 18 347–356the current understanding of AIP mutation-associated
pituitary adenomas as large, aggressive tumors in
young patients (Daly et al. 2010), which manifested in
these kindred as emergency presentations in both and
as pituitary apoplexy at the age of 12 years in one twin.
The role of AIP in predisposing to pituitary adenomas
was first described by Aaltonen’s group in 2006
(Vierimaa et al. 2006). Such patients are predisposed
preferentially to somatotropinomas and prolactinomas,
although non-secreting adenomas, Cushing disease and
thyrotropinomas also occur infrequently. In these FIPA
kindred, the diagnosis in both twins was consistent
with a silent somatotrope pituitary macroadenoma.
This diagnosis is supported by the lack of growth
disorders and other clinical symptoms or signs
attributable to somatotrope hypersecretion. Owing to
this lack of suggestive symptoms or signs in advance of
emergency presentation, the standard hormonal
workup (including dynamic pituitary function tests)
was not available before surgery. For this reason,
although the current patients were unlikely to have the
very elevated GH levels and concomitant symptoms
typical of AIP-mutation-related somatotropinomas
(Daly et al. 2010), more subtle abnormalities in the
somatotrope axis such as those commonly seen in CNC
cannot be ruled out (Boikos & Stratakis 2006). The
pathological designation is suggested by the presence
of scattered GH-positive cells (Figs 3C and 4C) and
immunoreactivity for Pit-1 (Figs 3E and 4E). As only
exceptional cells were immunoreactive for prolactin in
both adenomas, this observation was considered
insufficient to classify these adenomas as somato-
mammotrope (Asa 2008, Osamura et al. 2008).www.endocrinology-journals.orgThe most important finding on histological study of
these two tumors suggests that pituitary hyperplasia
may accompany pituitary tumor formation against
a background of an AIP mutation. Histopathological
diagnosis of somatotrope pituitary hyperplasia may be
difficult due to the high concentration of somatotrope
cells in the lateral wings of the adenohypophysis and
the interpretation of expanded acini on reticulin
staining can be prone to subjectivity. In both tumors,
reticulin staining demonstrated clearly enlarged acini
in the hyperplastic regions compared with normal
adenohypophysis (Figs 5A–C and 6A–C). Areas of
transformation from hyperplasia to adenoma were seen
(Figs 5D and 6D), which are rarely noted in surgical
samples in the absence of hyperplasia. Although
MIB1/Ki67 immunostaining is not recognized as a
criterion to confirm pituitary hyperplasia, the prolifer-
ation index clearly increased from low in residual
normal pituitary and hyperplasia to high in adenoma
(Figs 6F, 3D and 4D). Immunohistochemistry demon-
strated that the hyperplastic regions in both tumors
stained positively for GH, indicating their derivation
from somatotropes (Figs 5E, F and 6E). Hyperplastic
and adenomatous areas stained uniformly for Pit-1,
supporting a common developmental lineage (Figs 5G
and 6G). Importantly, these zones of hyperplasia did
not display LOH for the E216X mutation, unlike the
LOH observed in adenomatous tissue. LOH is an
established feature in pituitary tumors associated with
germline AIP mutations (Vierimaa et al. 2006, Daly
et al. 2007, Leontiou et al. 2008). These results were
also confirmed by AIP immunostains (Figs 3F, 4F, 5H
and 6H). Indeed, in hyperplastic areas in both tumors,353
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the cells stained strongly positive for AIP, although in
both adenomas, the immunoreactivity was very weak.
Staining was not completely absent as the E216X
mutation affects exon 5 (i.e. the epitope is preserved)
and low levels of mutated protein are likely to be
expressed as have been seen for multiple other AIP
mutations (Jaffrain-Rea et al. 2009).
Hyperplasia of the type seen in this study is not a
feature of MEN1-related pituitary adenomas, the other
frequent known genetic cause of familial pituitary
adenomas. As shown by Trouillas et al. (2008) in a
large case–control study, somatotrope hyperplasia was
found in only 3/77 MEN1 pituitary tissues, with 2/3
being caused by GHRH hypersecretion from a
pancreatic tumor. Pituitary hyperplasia is, however,
characteristic of patients with CNC and acromegaly
(Pack et al. 2000), although the tumor multicentricity
seen in CNC has not been seen to date in the setting of
AIP mutations. In contrast to the tumors in this study
where the hyperplastic areas were immunoreactive for
GH only, pituitary hyperplasia in CNC is characterized
by GH and prolactin immunoreactivity (Boikos &
Stratakis 2006). McCune–Albright syndrome (MAS)
is also associated with acromegaly and disorders of
both GH and prolactin secretion in which diffuse
somatomammotrope hyperplasia accompanying the
adenoma has been described (Kovacs et al. 1984,
Dumitrescu & Collins 2008). In CNC and MAS,
patients may exhibit elevations in hormone levels in
the absence of an overt adenoma. However, among
carriers of AIP mutations, no similar disorder has been
noted to date (Beckers & Daly, personal communi-
cation), which suggests that hormonal abnormalities
associated with AIP mutations are due to the adenoma
itself, without a major contribution from any hyper-
plasia possibly present. In MEN1 and CNC, multiple
pituitary tumors may be seen, which again has not been
noted in the setting of AIP mutation-related pituitary
adenomas (Magri et al. 2010).
In summary, we describe a hyperplasia–adenoma
sequence in pituitary tumorigenesis against a back-
ground of a novel AIP germline mutation (E216X).
The clinical presentation, in two non-identical twin
females carrying this same AIP germline mutation, was
remarkably similar with pituitary macroadenomas and
acute symptom onset in young patients. The tumor
genetic and pathological findings were virtually
identical in both patients, who presented with unusual
silent somatotrope adenomas. For the first time,
pituitary hyperplasia that was not accompanied by
LOH for the AIP gene has been described; this differs
from LOH findings in the tumor tissue. Our study
suggests that AIP LOH might be a late event in the354pituitary tumorigenesis sequence since LOH was
observed in the adenoma and was absent in hyper-
plastic regions, whereas normal AIP immunostaining
was preserved in the hyperplastic regions and largely
lost in the adenomatous tissue. This raises the
possibility of other genetic events occurring as
concomitant drivers of pituitary tumorigenesis (e.g.
digenic disease), which may help explain the current
low or moderate penetrance of pituitary adenomas
among carriers of AIP germline mutations. As pituitary
hyperplasia may be a feature of other patients with AIP
mutations (Stratakis et al. 2010) or in patients with
gigantism (Scheithauer et al. 1995), which is itself
frequently associated with AIP mutations, studies
combining large numbers of pituitary tumors of
differing AIP mutation origin could elucidate the
potential role of hyperplasia in the development of
pituitary adenomas in individuals with germline AIP
mutations.Declaration of interest
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